The global mammalian cell fermentation technology market is on a remarkable growth trajectory, with projections indicating a substantial increase to USD 68 billion by 2034. This marks a significant rise from the current market valuation of USD 45.9 billion in 2024, driven by a robust Compound Annual Growth Rate (CAGR) of 10% over the next decade.
The growth of the mammalian cell fermentation technology market is fueled by several key factors. The escalating prevalence of chronic diseases and a rapidly expanding aging population are primary contributors to this upward trend. These demographic and health-related shifts are driving the rising demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and therapeutic proteins—products that are predominantly produced using advanced mammalian cell fermentation technology.
Fetch Your Sample Report Encompassing The Latest Market Trends
The expanding pipeline of biologic drugs, encompassing novel therapeutics and biosimilars, is further stimulating the demand for mammalian cell fermentation technology. Additionally, the increasing number of biologic drug approvals and clinical trials is bolstering market growth.
Regulatory agencies worldwide have established comprehensive guidelines and standards for the development, manufacturing, and approval of biopharmaceuticals produced through mammalian cell fermentation technology. This supportive regulatory environment ensures product quality, safety, and efficacy, thereby fostering market growth.
Pharmaceutical companies, biotechnology firms, and contract manufacturing organizations (CMOs) are making substantial investments in expanding their biopharmaceutical manufacturing capabilities. These investments, encompassing bioreactor systems, infrastructure, and expertise, are significant drivers of market growth.
Moreover, the paradigm shift towards personalized medicine and targeted therapies has led to the development of biologic drugs tailored to individual patient profiles. Mammalian cell fermentation technology plays a pivotal role in enabling the production of personalized biologics, thus contributing to the expansion of this emerging field.
The robust growth trajectory of the mammalian cell fermentation technology market underscores its vital role in the biopharmaceutical industry’s evolution. With increasing investments, supportive regulations, and advancements in personalized medicine, the market is poised for remarkable expansion in the coming years.
Key Takeaways:
- From 2019 to 2023, the mammalian cell fermentation technology market expanded at a CAGR of 11.4%.
- Based on the type, the Chinese Hamster Ovary (CHO) Cell Fermentation segment is expected to rise at a CAGR of 3.8% through 2034.
- The mammalian cell fermentation technology demand in China is predicted to grow at a CAGR of 4.8% through 2034.
- In the United States, the mammalian cell fermentation technology industry is estimated to register a CAGR of 4.2% from 2024 to 2034.
- The United Kingdom is projected to expand by a CAGR of 5.0% between 2024 and 2034.
- The mammalian cell fermentation technology market in Japan is anticipated to record a CAGR of 5.5% during 2034.
“The combination of increasing demand for biopharmaceuticals, advancements in biotechnology, supportive regulatory environment and technological innovations are key drivers fueling the growth of the mammalian cell fermentation technology market,” says an FMI analyst.
Access Comprehensive Insights Now – Propel Your Business Forward
Competitive Landscape:
Market players prioritize customer satisfaction by offering tailored solutions, technical support, and responsive customer service. Understanding customer needs, providing timely assistance, and fostering long-term relationships are essential for building brand loyalty and gaining a competitive advantage in the market.
- In October 2023, Vaxcyte, Inc. and Lonza unveiled a new commercial manufacturing partnership, building upon their ongoing collaboration. This agreement is poised to facilitate the potential global distribution of Vaxcyte’s PCV candidates, namely VAX-24 and VAX-31, catering to both adult and pediatric populations.
- Leveraging Lonza’s existing infrastructure, this collaboration is expected to propel clinical development efforts forward and pave the way for the anticipated initial release of VAX-24 in the United States for adult use.
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher
- Lonza
Mammalian Cell Fermentation Technology Market – Key Segments:
By Type:
- Chinese Hamster Ovary (CHO) Cell Fermentation
- Human Embryonic Kidney (HEK) Cell Fermentation
- Baby Hamster Kidney (BHK) Cell Fermentation
- Murine Myeloma Cell Fermentation
- Other Types
By Application:
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Hormones
- Enzymes
- Other Application
By End Use:
- Biopharmaceutical Companies
- CMOs & CDMOs
- Academic & Research Institutes
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- The Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
